Onyx Biotec Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Onyx Biotec Ltd is ₹ 33 as of 30 Apr 15:30 . The P/E Ratio of Onyx Biotec Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Onyx Biotec Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Onyx Biotec Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Onyx Biotec Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Onyx Biotec Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Onyx Biotec Ltd changed from 0 % to 0 % over 9 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 9 quarters. This represents a CAGR of -100.00% .

About Onyx Biotec Ltd

Onyx Biotec Limited was incorporated as Onyx Biotec Private Limited', pursuant to a Certificate of Incorporation dated May 13, 2005 issued by the Registrar of Companies, Punjab, H.P. & Chandigarh.
Further, Company converted into a Public Limited and the name was changed to Onyx Biotec Limited' and a fresh Certificate of Incorporation dated July 23, 2024 was issued by the Registrar of Companies, Central Processing Centre. Onyx started its operation in pharmaceutical industry with sterile water for injections with capacity of 2 lacs units per day in year 2010.
Since then, Onyx is engaged in Manufacturing of Pharmaceutical Products such as sterile water ampoule, dry injection, dry syrup etc. to major corporations, which includes the top pharma companies. Presently, the Company manufactures Sterile Water for Injections, and acts as a pharmaceutical contract manufacturer offering a comprehensive range of Dry Powder Injections and Dry Syrup for India and overseas.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Onyx Biotec Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Onyx Biotec Ltd or Sanofi India Ltd?

Market cap of Onyx Biotec Ltd is 59 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Onyx Biotec Ltd and Sanofi India Ltd?

The stock performance of Onyx Biotec Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Onyx Biotec Ltd and Sanofi India Ltd?

As of May 4, 2026, the Onyx Biotec Ltd stock price is INR ₹33.0. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Onyx Biotec Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Onyx Biotec Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.